EM1602H "Trials and Tribulations: Progress and Controversies in Diabetes, 2016" (IM GR-021216)

The diabetes epidemic has spawned new interventions, numerous new trials to study those interventions, and an increasing appreciation that prevention and effective treatment aimed at reducing the development of diabetes and its associated morbidity and mortality are critical to public health. While the clinical trials have demonstrated the means of reducing the development of type 2 diabetes and of decreasing the long-term complications of both type 1 and type 2 diabetes, numerous clinically important questions remain. This presentation will review the major advances in diabetes prevention and treatment from the past 30 years and will identify the areas that require further study.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Understand the long-term complications of diabetes and the glycemic interventions that have been effective in reducing them.
  • Enumerate the major risk factors for type 2 diabetes and the preventative measures that have been effective in reducing the development of type 2 diabetes.
  • Understand the differences and similarities in response of microvascular and cardiovascular complications to glycemic interventions.
  • Understand the major challenges to diabetes treatment in the setting of the current-day epidemic.
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
Course expires: 

David M. Nathan, M.D
Director, Diabetes Center and Clinical Research Center
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Leonard L. Madison, M.D., Visiting Professorship in Diabetes, Endocrinology, and Metabolism

Available Credit

  • 1.00 AMA


Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome